RTP Mobile Logo
Select Publications

Michael A Davies, MD, PhD

Eggermont AMM et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. ESMO 2020;Abstract LBA46.

Gershenwald JE et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(6):472-92. Abstract

Hauschild A et al. Long-term benefit of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected stage III BRAF V600-mutant melanoma: Five-year analysis of COMBI-AD. ASCO 2020;Abstract 10001.

Mueller KL et al. Neoadjuvant therapy for melanoma: A US Food and Drug Administration — Melanoma Research Alliance public workshop. Clin Cancer Res 2020;clincanres.3285.2020. Abstract

Versluis JM et al. Rationalizing the pathway to personalized neoadjuvant immunotherapy: The Lombard Street Approach. J Immunother Cancer 2020;8(2):e001352. Abstract

Weber J et al. Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. ESMO 2020;Abstract 1076O.

Zimmer L et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;395(10236):1558-68. Abstract

Karl D Lewis, MD

Ascierto PA et al. Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer 2020;126:33-44. Abstract

Ascierto PA et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med 2019;25(6):941-6. Abstract

Gutzmer R et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;395(10240):1835-44. Abstract

Hamid O et al. Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: Results from a phase I trial of atezolizumab. Clin Cancer Res 2019;25(20):6061–72. Abstract

Larkin J et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371(20):1867-76. Abstract

Long GV et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371(20):1877-88. Abstract

Ribas A et al. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res 2020;26(1):46-53. Abstract

Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381(7):626-36. Abstract

Robert C et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30-3. Abstract